Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Virol Methods ; 320: 114787, 2023 10.
Article in English | MEDLINE | ID: mdl-37516366

ABSTRACT

Viral infections have been the cause of high mortality rates throughout different periods in history. Over the last two decades, outbreaks caused by zoonotic diseases and transmitted by arboviruses have had a significant impact on human health. The emergence of viral infections in different parts of the world encourages the search for new inputs to fight pathologies of viral origin. Antibodies represent the predominant class of new drugs developed in recent years and approved for the treatment of various human diseases, including cancer, autoimmune and infectious diseases. A promising group of antibodies are single-domain antibodies derived from camelid heavy chain immunoglobulins, or VHHs, are biomolecules with nanometric dimensions and unique pharmaceutical and biophysical properties that can be used in the diagnosis and immunotherapy of viral infections. For viral neutralization to occur, VHHs can act in different stages of the viral cycle, including the actual inhibition of infection, to hindering viral replication or assembly. This review article addresses advances involving the use of VHHs in therapeutic propositions aimed to battle different viruses that affect human health.


Subject(s)
Antiviral Agents , Single-Domain Antibodies , Virus Diseases , Single-Domain Antibodies/therapeutic use , Animals , Camelidae/metabolism , Antiviral Agents/therapeutic use , Molecular Targeted Therapy , Virus Diseases/drug therapy , Virus Diseases/virology , Humans , Viruses/classification
SELECTION OF CITATIONS
SEARCH DETAIL
...